Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies

The number of elderly patients with cancer has increased due to aging of the population. However, safety of programmed cell death-1 (PD-1) or programed cell death ligand 1 (PD-L1) inhibitors in elderly patients remains controversial, and limited information exists in frail patients. The present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakakida, Tomoki, Ishikawa, Takeshi, Uchino, Junji, Tabuchi, Yusuke, Komori, Satoshi, Asai, Jun, Arai, Akihito, Tsunezuka, Hiroaki, Kosuga, Toshiyuki, Konishi, Hirotaka, Hongo, Fumiya, Inoue, Masayoshi, Hirano, Shigeru, Ukimura, Osamu, Taguchi, Tetsuya, Takayama, Koichi, Itoh, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406883/
https://www.ncbi.nlm.nih.gov/pubmed/32774487
http://dx.doi.org/10.3892/ol.2020.11875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7406883/
https://www.ncbi.nlm.nih.gov/pubmed/32774487
http://dx.doi.org/10.3892/ol.2020.11875

Ejemplares similares